TY  - GEN
AU  - Ocio, Enrique M
AU  - Perrot, Aurore
AU  - Bories, Pierre
AU  - San-Miguel, Jesus F
AU  - Blau, Igor W
AU  - Karlin, Lionel
AU  - Martinez-Lopez, Joaquin
AU  - Wang, Song-Yau
AU  - Bringhen, Sara
AU  - Marcatti, Magda
AU  - Mateos, María-Victoria
AU  - Rodriguez-Otero, Paula
AU  - Oliva, Stefania
AU  - Nogai, Axel
AU  - Le Roux, Nadia
AU  - Dong, Liyan
AU  - Macé, Sandrine
AU  - Gassiot, Matthieu
AU  - Fitzmaurice, Thomas
AU  - Oprea, Corina
AU  - Moreau, Philippe
PY  - 2023
DO  - 10.1038/s41375-023-01936-7
UR  - https://hdl.handle.net/20.500.12105/23123
AB  - Patients with newly diagnosed multiple myeloma (NDMM) ineligible for autologous stem cell transplantation (ASCT) have lower survival rates and may benefit from frontline regimens that include novel agents. This Phase 1b study (NCT02513186) evaluated...
LA  - eng
PB  - Nature Publishing Group
KW  - Multiple Myeloma
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Lenalidomide
KW  - Bortezomib
KW  - Transplantation, Autologous
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Dexamethasone
TI  - Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation
TY  - research article
ER  -